Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2013

View Archived Issues

Phase III evaluation of a polymerase inhibitor for the treatment of drug-resistant hepatitis C

First-in-human results presented for the imaging agent [18F]FC-119S

Researchers at Biota Scientific Management present new antiviral agents

Hereditary fibrosing poikiloderma, a new condition caused by FAM111B gene mutations

Novel biomarker associated with suicide attempt in patients with MDD

Pfizer presents phase I results for a novel biosimilar of trastuzumab

Ocriplasmin receives initial recommendation for NHS reimbursement in U.K.

NeuroVive Pharmaceutical reports new collaboration and milestone payment from Sihuan

Natural derived polymer VS-501 may control serum phosphate in CKD

Derma Sciences reports data from pharmacokinetic study of DSC-127

Amgen and Cytokinetics expand license for omecamtiv mecarbil

Teprotumumab to be developed in new indication

Aphios and VivaCell to develop non-psychotropic cannabinoids

Ferrer completes phase III trial of ozenoxacin in impetigo

Roche presents new CB2 receptor agonists

Amgen reports topline results from phase III TRINOVA-1 trial

Constellation Pharmaceuticals prepares new EZH2 inhibitors for cancer

Chinese researchers patent novel HIV fusion inhibitors

Bioheart completes phase I ANGEL study

New DHODH inhibitors for malaria presented by Chinese researchers

Funding supports Madera's development of small-molecule drugs for Alzheimer's disease

Bill & Melinda Gates Foundation and European Commission partner

Nanobiotix cleared to begin study of NBTXR-3 for head and neck cancer

Exact Sciences completes PMA application for Cologuard screening test

Constella launched in Europe for the treatment of IBS-C

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...